Malignant Pleural Mesothelioma Clinical Trial
Official title:
A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma
RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill
or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is
currently used safely as in intra-operative treatment for malignant pleural mesothelioma.
This study is aimed to determine if the addition of gemcitabine as a second intracavitary
chemotherapy can be accomplished safely.
PURPOSE: This is a Phase I trial to study the efficacy of combination chemotherapy
consisting of gemcitabine and cisplatin administered in the operating room and put into the
chest and abdomen for one hour. We are also looking at the effects of heating the
chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents:
amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy.
- This is a dose escalation study of gemcitabine with a fixed dose of cisplatin
- Patients will undergo cytoreductive surgery, which entails the removal of the inner and
outer lining of the lung (pleurectomy/decortication) with or without the lung itself
(extrapleural pneumonectomy), including the lining overlying the pericardium and
diaphragm. Resection of the pericardium and diaphragm are occasionally necessary to
remove all visable tumor. This surgery is part of standard care for malignant pleural
mesothelioma.
- After surgery, a one hour lavage with heated cisplatin and or gemcitabine will be
administered to the hemithorax (and abdominal regions if the diaphragm is no longer
present).
- Patients will remain hospitalized until they have recovered from surgery (usually 7-14
days).
- Patients will return to the hospital during the first month after their surgery to be
evaluated by the medical staff.
- Dose escalation: 1) Three patients will be treated at the first dose level of
gemcitabine. Labs will be monitored on a weekly basis, including a CBC, Chem-7, and
LFT's. In the absence of developing dose-limiting toxicity (DLT) among the first 3
patients treated, dosages can be escalated. DLT will be defined as any grade 3 or
higher renal toxicity, thrombocytopenia or other grade 3 toxicity not related to
surgery 2) If none of these 3 patients have any toxicity, we will proceed to the next
level of gemcitabine. 3) If DLT occurs in 1 of 3 patients at a given dose level, then 3
additional patients are added at that dose (for a total of 6 at this level)If no DLT
occurs, we will proceed to the next level of gemcitabine. If DLT occurs in another
patient, this dose is considered the maximum tolerated dose (MTD). 4) At any dose, 3
cases of DLT lead to discontinuation of recruitment at that dose and enrollment of 3
additional patients at a lower dose.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06037941 -
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
|
N/A | |
Completed |
NCT01675765 -
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
|
Phase 1 | |
Withdrawn |
NCT04201145 -
Pembrolizumab + Defactinib In Pleural Mesothelioma
|
Phase 1 | |
Completed |
NCT03048474 -
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT02369198 -
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
|
Phase 1 | |
Terminated |
NCT01870609 -
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT00886028 -
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00272558 -
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT02436733 -
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
|
Phase 2 | |
Completed |
NCT04843007 -
Alvopem® (Pemetrexed) Safety Assessment
|
||
Completed |
NCT01721018 -
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00797719 -
Short Neoadjuvant Hemithoracic IMRT for MPM
|
Phase 1/Phase 2 | |
Completed |
NCT00386815 -
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Completed |
NCT04775446 -
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
|
||
Completed |
NCT01644994 -
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
Completed |
NCT01865045 -
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
|
||
Recruiting |
NCT01343264 -
Trimodality Therapy for Malignant Pleural Mesothelioma
|
N/A | |
Active, not recruiting |
NCT04162015 -
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
|
Phase 1 | |
Recruiting |
NCT04400539 -
The IMmunotherapy Pleural 5-ALA PDT
|
Phase 2 |